On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading supplier of subscription-based health and wellness products in the Nordic region. The company was established in Norway in 2002 and at Impilo’s entry in 2017, the company had a strong presence in Norway, Sweden, Finland, Czech Republic and an emerging presence in Denmark.
Impilo’s divestment of NutraQ to Orkla completed On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities.
NutraQ is a leading supplier of subscription-based health and wellness products in the Nordic region. The company was established in Norway in 2002 and at Impilo’s entry in 2017, the company had a strong presence in Norway, Sweden, Finland, Czech Republic and an emerging presence in Denmark.
“We are highly impressed by the achievements and execution abilities of the NutraQ organization – led by CEO Gustaf S Christensen – transforming the company from a successful founder led Nordic D2C business into a world-class, data driven and digitalized D2C platform across several Northern European markets”, says Magnus Edlund, partner at Impilo.
During Impilo’s ownership, the company has expanded its footprint significantly – both geographically and concept-wise – alongside with an enhanced professionalization and digitalization of operations. Over the past three years, revenues and earnings have grown w. ca. 20% and 30% per year, respectively, with continued strong momentum in 2021.
“NutraQ’s management was given a clear mandate from its owners and board of directors to accelerate growth, operational efficiency, and geographical expansion and it has been a pleasure to lead that effort. NutraQ is today a high performing D2C platform – and with Orkla as a new owner – we can further accelerate our plans to expand geographically and across new product categories” says Gustaf S Christensen, CEO of NutraQ.
“The combination of an active ownership model deployed by the partnership between Impilo and NutraQ’s founders and strong independent board members formed an effective governance model during a very busy transformational period. I am convinced that Orkla is an ideal new home for the business, perfectly fit to support NutraQ’s continued development.” says Henning Søgaard, Chairman of the Board since 2018.
News
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.